Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBCLaura M. Spring, Leif W. Ellisen, Veerle Bossuyt et al.|Cancer Research|2024Cited by 2